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Advantages of Radiochemistry in Microliter
Volumes
Pei Yuin Keng, Maxim Sergeev, and R. Michael van Dam
Abstract Positron emission tomography (PET) provides quantitative 3D visuali-
zation of physiological parameters (e.g., metabolic rate, receptor density, gene
expression, blood flow) in real time in the living body. By enabling measurement
of differences in such characteristics between normal and diseased tissues, PET
serves as vital tool for basic research as well as for clinical diagnosis and patient
management. Prior to a PET scan, the patient is injected with a short-lived tracer
labeled with a positron-emitting isotope. Safe preparation of the tracer is an
expensive process, requiring specially trained personnel and high-cost equipment
operated within hot cells. The current centralized manufacturing strategy, in which
large batches are prepared and divided among many patients, enables the most
commonly used tracer (i.e., [18F]FDG) to be obtained at an affordable price.
However, as the diversity of tracers increases, other strategies for cost reduction
will become necessary. This challenge is being addressed by the development of
miniaturized radiochemistry instrumentation based on microfluidics. These com-
pact systems have the potential to significantly reduce equipment cost and shielding
while increasing diversity of tracers produced in a given facility. The most common
approach uses “flow-through” microreactors, which leverage the ability to precisely
control reaction conditions to improve synthesis times and yields. Several groups
have also developed “batch” microreactors which offer significant additional
advantages such as reduced reagent consumption, simpler purifications, and excep-
tionally high specific activity, by reducing operating volumes by orders of magni-
tude. In this chapter, we review these “batch” approaches and the advantages of
using small volumes, with special emphasis on digital microfluidics, in which
reactions have been performed with volumes as low as ~1 μL.
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7.1 Introduction
7.1.1 Radiosynthesis of Positron Emission Tomography
Tracers
Positron emission tomography (PET) is an extremely powerful, noninvasive diag-
nostic imaging technology capable of measuring a plethora of biological processes
in vivo [1]. In research, PET can provide dynamic information about normal or
diseased states of a living organism and, in the clinic, can provide information that
is critical for diagnosis, selection of therapy, or monitoring response to therapy. In
some cases, PET can detect biochemical changes associated with disease before any
anatomical changes can be observed [2].
PET requires injection of a tracer labeled with a positron-emitting isotope, such
as fluorine-18, nitrogen-13, oxygen-15, carbon-11, or a radiometal. Fluorine-18
possesses physical and nuclear properties that are particularly desirable for
radiolabeling and imaging [3]. For example, the low positron energy and range
ensure high-resolution imaging while minimizing radiation exposure to the patient.
In addition, the 110 min half-life is sufficiently long for multistep synthesis,
transport to the imaging site, and imaging over extended periods.
Due to the hazard of working with radioactive materials, a specialized infra-
structure of automated radiosynthesizers operating in radiation-shielded “hot cells”
by expert personnel is required. Due to the high costs, a couple of tracers (including
2-[18F]fluoro-2-deoxy-D-glucose, [18F]FDG) are currently produced in a “satellite”
manner. Radiopharmacies manufacture large batches that are subdivided among
many patients within a local area to leverage economies of scale and offer the
compound at an affordable price. As the diversity of PET tracers used in medical
care and research increases, opportunities to share costs are reduced, and alternative
innovative approaches are needed to reduce the high cost of each batch.
A particularly promising approach is the development of miniaturized
radiosynthesizers based on microfluidic technology that can enable dramatic reduc-
tions in the cost of equipment and the amount of radiation shielding needed. An
additional innovation is the concept of disposable “cassettes,” which allows each
synthesizer to make a wide range of tracers simply by using different cassettes,
rather than being dedicated to production of a single tracer [4].
7.1.2 Microfluidics for Radiosynthesis
It has been well established that the geometry of microfluidic devices offers many
advantages for the synthesis of short-lived radiopharmaceuticals [5–7]. In particu-
lar, the small dimensions enable improved control of reaction conditions via rapid
mixing and efficient heat transfer, leading to faster reactions and improved selec-
tivity, thus higher yields.
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Most commonly in the field of radiochemistry, these devices are based on “flow-
through” microreactors, where reactions occur by flowing reagent streams through
mixers and preheated capillary tubes or microchannels. Numerous groups have
demonstrated the radiosynthesis of [18F]FDG in polymer chips [8], glass chips [9],
and capillary tubes [10]. This technology has been commercialized (e.g., Advion
Biosciences “NanoTek” and Scintomics “μ-ICR”), and dozens of different radio-
tracers labeled with F-18, C-11, N-13, and Tc-99 m have been demonstrated
[11]. Recent advances have enabled the integration of solvent exchange processes
[12, 13], which previously were accomplished via bulky, off-chip subsystems.
Because it is important that flow-through systems are completely filled with
liquid in order to achieve accurate fluid handling, typical operating volumes are
comparable to macroscale systems (i.e., >500 μL). Another class of microfluidic
device based on small (<50 μL) volumes known as “batch” microreactors have also
been used for radiochemistry (Fig. 7.1). These devices are particularly attractive for
radiochemistry because all synthetic steps including solvent exchange can be
integrated into a single chip and because small volumes can reduce reagent con-
sumption, enhance reaction kinetics, improve specific activity, reduce radiolysis,
and simplify purification, as described below.
7.1.3 Platforms for Microliter Volume Synthesis
The first batch microfluidic synthesis of [18F]FDG was demonstrated in a
polydimethylsiloxane (PDMS) chip with 40 nL reaction volume [14]. Microvalves
Fig. 7.1 Batch microfluidics devices for synthesis of PET tracers: (a) PDMS chip with 40 nL reactor
(Adapted from reference [14] with permission from AAAS). (b) Scaled-up PDMS chip with 5 μL
reactor (Adapted from reference [15], Copyright © 2010 by the Society of Nuclear Medicine and
Molecular Imaging, Inc.). (c) Chemically inert polydicyclopentadiene (pDCPD) polymer chip with
5 μL reactor (Reproduced from reference [56]). (d) Chemically inert pDCPD chip with 60 μL reactor
(Reproduced with permission from reference [50], Copyright © 2010 John Wiley & Sons, Ltd.). (e)
PDMSchip for optimizing radiolabeling reaction in variable volume droplets (~100 nL) (Reproduced
with permission from reference [59], Copyright © 2015 IOP Publishing). (f) PDMS chip for
radiometal labeling with 25 μL reaction volume (Reproduced with permission from reference [19],
Copyright © 2013 Elsevier, Inc.) (g) EWOD chip with reaction volume ranging from 2 to 17 μL
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were used to close the reactor during reaction steps, and the permeability of the
PDMS enabled escape of vapor for solvent exchange processes. By scaling up the
reactor volume to 5 μL, it was possible to produce mCi amounts of [18F]-labeled
tracers [15]. Unfortunately, due to adverse interaction of PDMS with [18F]fluoride
[16], radioactivity losses were high and reliability was low. Using inert plastic
materials as the reaction vessel improved reliability, and a system with 50 μL
reaction volume enabled production of tracers of sufficient quantity and quality
for human imaging [17], establishing the relevance of the micro-batch format.
While the PDMS chip was not suitable for processing [18F]fluoride, the capa-
bility to react small volumes was found to be useful for screening radiolabeling
conditions for the reaction of [18F]SFB with an engineered antibody [18]. Using
<100 nL per droplet, many reaction conditions could be tested, and then the whole
batch could be labeled once optimal conditions were found. A quasi-continuous-
flow PDMS chip using small volumes (25 μL) has also been used for radiolabeling
peptides and proteins with radiometals such as Ga-68 and Cu-64 [19]. The small
volume enabled improved stoichiometry of the label and ligand, dramatically
improving the labeling yield and potentially avoiding the need for extensive
purification.
Recently, our group demonstrated successful radiosynthesis of [18F]FDG and
other molecules using another type of batch microfluidic device based on the digital
manipulation of droplets between two parallel plates [20, 21] known as
electrowetting-on-dielectric (EWOD). Droplets are controlled by on-chip elec-
trodes (Fig. 7.2), eliminating the need for bulky valve actuators, pumps, and
radiation shielding as is needed in the approaches mentioned above. A wide
range of reagents and reaction conditions can be used on these EWOD microchips
because they are constructed from inert and thermally stable materials (glass
substrate, metallic electrode layer, inorganic dielectric layer, and fluoropolymer
layer). Because droplets are surrounded by gas, evaporation and solvent exchange
can readily be performed on the chip. Resistive heating, temperature sensing for
precise temperature control, and impedance sensing for measuring electrical prop-
erties of liquid can all be integrated on the chip without the need of additional bulky
hardware [22].
Using this platform, our laboratory has reported the successful synthesis of [18F]
FDG [20], 3-[18F]fluoro-30-deoxy-fluorothymidine ([18F]FLT) [23], [18F]fallypride
[24], and N-succinimidyl 4-[18F]fluorobenzoate ([18F]SFB) [25] with radiochemi-
cal yields of 22 8 % (n¼ 11), 63 5 % (n¼ 5), 65 6 % (n¼ 7), and 19 8 %
(n¼ 5), respectively. The final 18F-labeled compounds passed all quality control
tests required by the United States Pharmacopeia for injection into humans and
have been successfully used in preclinical PET. The syntheses of [18F]FDG and
[18F]FLT on a simplified EWOD chip have also been reported by others
[26, 27]. These results suggest that the EWOD-based synthesizer can meet the
requirements for on-demand production of diverse PET tracers to meet preclinical
or clinical needs.
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7.2 Advantages of Radiosynthesis at the Microliter Scale
7.2.1 Miniaturization and Disposability
Perhaps the most significant potential advantage of batch microfluidics in the field
of radiochemistry is the potential to integrate the entire synthesis, purification, and
formulation apparatus into an extremely compact system. Size of the components
that need to be shielded (because they contain or contact radioactivity) has a
tremendous impact on the amount of radiation shielding needed. For a constant
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Fig. 7.2 Structure and operation of EWOD microfluidic chips. (a) Illustration of the
“electrowetting” effect. (b) Schematic of typical EWOD device with droplet sandwiched between
the two plates. (c) Applying a local field to one end of the droplet using a small control electrode
(typically 1 or 2 mm square) can generate a force on the droplet in a direction toward the activated
electrode (Diagram courtesy of Robin Garrell). This force enables several operations, including
(d) droplet transport along a predetermined path, (e) droplet splitting, and (f) droplet dispensing
from an on-chip reservoir. Incorporation of specialized heating electrodes permits additional
operations such as (g) evaporation of solvent. ((d) is reproduced with permission from reference
[60] (Copyright © 2004 American Chemical Society), (e) is reproduced with permission from
reference [61] (Copyright © 2003 IEEE), (f) is reproduced from reference [62] with permission of
The Royal Society of Chemistry.)
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Shielding volume
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where r is the dimension of the synthesizer. Assuming a fixed shielding thickness
where t r, the scale factor is proportional to r2. Thus, moving from macroscale
systems with ~20-inch dimensions to microfluidic chips with ~2-inch dimensions
can reduce the needed shielding 100-fold. This reduction could make it practical for
radiochemistry chips to be used in benchtop situations instead of needing to operate
them in specialized facilities equipped with hot cells and mini cells to shield
radiation, thus removing one of the bottlenecks in PET tracer production.
Integrating the fluid pathways of a radiosynthesizer into a microfluidic chip has
other advantages as well. If the chip can be made to be very inexpensive, the entire
fluid pathway can be discarded after each synthesis run, eliminating the need for
developing and validating a cleaning protocol and associated documentation or
cleaning the system on a daily basis. This concept of disposability is increasingly
being used in macroscale synthesizers to simplify setup, cleanup, and compliance
with cGMP manufacturing guidelines for PET tracers that are used in humans
[4]. Disposable cassettes also provide flexibility: with a single synthesizer instru-
ment, the operator can choose to install different disposable cassettes (with different
pre-configured fluid path configurations) along with matching reagent kits to make
different PET tracers [4].
7.2.2 Reduced Radiolysis
Radiolysis is the process of chemical bond cleavage caused by radiation. Molecules
of a PET probe undergo irradiation from both the starting [18F]fluoride (external
radiolysis) and from other radiolabeled molecules (autoradiolysis) [28–30], which
can lead to reduction in the yield of the probe and the formation of radioactive side
products. The mechanism of damage is believed to be related to the formation of
radical species in the solvent by high-energy particles [29]. While the final inject-
able formulation can be stabilized against autoradiolysis with addition of radical
scavengers (e.g., ethanol) to preserve radiochemical purity [30], this is not gener-
ally possible at earlier stages during the radiosynthesis process.
Fluorine-18 emits positrons with high energy (Emax¼ 0.633 MeV) that cause
ionization of the solvent while dissipating their kinetic energy along their travel
range. The range is up to ~2.4 mm, but due to the tortuous path they follow, the
distribution of final displacements of positrons from their origin is characterized by
a smaller range (i.e., full width at one third maximum ~1 mm) [31]. When the
reaction vessel dimensions (e.g., vial, flask, or Eppendorf tube: ~10 mm) are much
greater than this range, each positron deposits all of its energy into the solvent,
leading to extensive radiolysis (Fig. 7.3a).
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Rensch et al. have shown via simulations and experiments that the degree of
radiolysis is geometry dependent [3]. In vessels for which at least one dimension is
significantly smaller than the positron range (e.g., capillary tubing or EWOD
chips), there is significantly reduced radiolysis because positrons can escape the
solvent before depositing very much of their energy (Fig. 7.3b). For example, the
solvent within a 100 μm diameter capillary reactor absorbs only 10 % of the energy
Fig. 7.3 Illustration of radiolysis suppression. (a) Possible positron tracks from decay of a
fluorine-18 atom at the center of a conventional macroscale reaction vessel. Because the positron
range is significantly less than the reactor dimensions, the positron will deposit all of its energy
into the solvent, where it causes radiolysis. This is true of decay events happening throughout the
vial. (b) In contrast, in an EWOD microfluidic chip, one dimension of the solvent volume is very
thin compared to the positron range. Thus, a significant portion of the possible tracks are mostly or
entirely outside the droplet. Thus, most positrons will escape the solvent after having only
deposited a small fraction of their energy in the solvent, reducing radiolysis
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of positrons emitted from within the solvent, and a planar droplet geometry with
100 μm height (similar to the EWOD chip) absorbs only 40 % of the positron
energy [32]. Further reduction could be achieved by reducing the dimensions.
7.2.3 Reagent Minimization
Because batch microfluidic chips such as EWOD handle volumes that are 2–3
orders of magnitude less than conventional systems, the quantity of reagents needed
to perform reactions is proportionately reduced, thereby reducing the per-run
reagent cost. Generally the precursor is the most expensive reagent. In macroscale
synthesis, reagents for common small-molecule PET tracers can cost hundreds of
US$ for a single synthesis run (e.g., 10 mg in ~1 mL). Synthesis in microliter
volumes (e.g., 10–100 μg precursor) could reduce this cost down to dollars per run
(depending on costs of packing this small amount of reagent into vials), making it
economical to produce even small batches on demand for a single user.
Biomolecule-based precursors such as proteins are even more expensive, costing
up to thousands of US$ for a single synthesis. Using microliter volumes, the 100 s
of micrograms quantity typically used for protein labeling could be reduced to
microgram or submicrogram levels. Reducing the reagent consumption enables a
greater number of runs per a given amount of precursor or reduces the cost per run
of precursor.
Minimization of reagents can also simplify purification processes [19]. Typically
in 18F-radiochemistry, the amount of precursor is many of orders of magnitude
higher than the amount of [18F]fluoride to ensure the fluorination reaction occurs as
rapidly as possible. For example, in the synthesis of [18F]FDG, one typically uses
about 40 μmol of mannose triflate [33], compared to the 600 pmol of [18F]fluoride
ion in a 1000 mCi batch, representing an excess of 5 orders of magnitude. Even
accounting for typical final specific activity, the amount of [19F]fluoride + [18F]
fluoride is about 60–600 nmol, meaning there is still an excess of about 2–3 orders
of magnitude of precursor compared to ([18F] + [19F])FDG. This means that at the
end of the synthesis, there are vast amounts of unreacted (or hydrolyzed) precursor
that must be separated from a much smaller amount of the desired product. Because
of the high amounts or precursor, large reaction volume, and the chemical similarity
between precursor (native or hydrolyzed) and product, long semi-preparative
HPLC purification times may be needed, resulting in a large solvent volume in
the purified product. While suitable for patient use, these large volumes can be
problematic for imaging in small animals, where the tracer must be sufficiently
concentrated to inject enough radioactivity for imaging (typically 100–200 μCi)
within the maximum recommended injection volume to avoid physiological per-
turbation (e.g., <100 μL for mice). Using smaller amounts of reagents in
microfluidic formats, several groups have demonstrated that analytical-scale
HPLC is sufficient for purification [24, 34], resulting in more concentrated final
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formulation. Purification has also been successfully performed with on-chip struc-
tures similar to typical macroscale Sep-Pak cartridges [35–37].
Reduced amount of reagents may also simplify the quality control (QC) testing
that is needed prior to injection in humans. In general, the reduced amounts of
reagents and solvents will lead to reduced amounts of residual impurities after the
purification process. An interesting prospect of using extremely tiny volumes is that
if the total amount of reagent added is below the injectable limits set by various
regulatory agencies, then a test for the absence of that particular chemical may
become unnecessary.
7.2.4 High Specific Activity
The specific activity (SA) of a PET tracer (e.g., labeled with fluorine-18) is defined
as the ratio of the number of 18F-labeled molecules to the total number of 18F-
labeled and 19F-labeled molecules and is typically reported in units of radioactivity
per mass (e.g., Ci/μmol). For a certain desired injected dose (e.g., 10 mCi for
humans), the higher the SA, the lower the mass that is injected.
High SA of a PET tracer is important for several reasons. First, because many PET
tracers are based on pharmacologically active compounds, only a very low mass
should be injected to avoid eliciting a pharmacological response. Second, for tracers
that target low-abundance receptors (e.g., in neurological imaging), injecting lower
mass avoids saturation or high occupancy of the receptors. This is especially important
in small animal imaging, in which significantly higher radioactivity is injected (per
mass of the animal) compared to human subjects to achieve sufficient image quality
with the higher resolution (smaller voxel size) scanners that are used for animals
[38]. Third, highSAmay improve image quality by increasing the proportion of targets
occupied by radioactive forms of the tracer while reducing competitive interactions of
the nonradioactive forms. Other reasons to maximize SA are related to the logistics of
PET tracer production. Often, tracers need to be transported from the radiopharmacy
where they are produced to the imaging center. Because of the radioactive decay
during this transport time, the SA is reduced by a factor of 2 for each half-life, and a
high initial SA is needed to ensure sufficient SA at the time of imaging.
For fluorine-18, the maximum theoretical SA is 1710 Ci/μmol; however, the
actual SA of the final tracer is significantly lower, typically 1–10 Ci/μmol [39]. This
means the number of fluorine-18 atoms is dwarfed (~200–2000X) by the number of
fluorine-19 contaminant atoms. Some of the fluorine-19 contamination originates
due to the equipment and materials used in the [18F]fluoride production process
(e.g., [18O]H2O quality, volume of target, target materials, tubing materials, target
loading/unloading process, etc.) [40–42]. While such sources may be out of most
radiochemists’ control, another significant contribution is the contamination of
reaction mixture with extra fluorine-19 fluoride during the synthesis process itself
(i.e., all steps upstream of and including the fluorination step). The main sources are
the QMA cartridges used in the fluoride drying process, fluorinated materials (e.g.,
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Teflon tubing and stirbars) [43], and the reagents used in the synthesis, such as
K2CO3, Kryptofix, etc.
In preliminary studies, our group observed that microfluidic synthesis on EWOD
chips resulted in significantly higher (up to 25–50 times) SA compared to macro-
scale synthesis, starting with the same amount of radioactivity [23, 24]. This
suggested the potential for microfluidics to significantly reduce fluorine-19 con-
tamination in the synthesis process. An in-depth investigation led to the observation
that the dependence of SA on reaction parameters was very different for macroscale
(100–5000 μL) and microscale (2–8 μL) syntheses. At the macroscale, the SA
strongly varied with the reaction volume (amount of reagents) as well as the starting
radioactivity (from 10s to 100 s of mCi), whereas the SA was much higher and
nearly constant (20–23 Ci/μmol), under all conditions when performed in
microdroplets. These results suggest that in the macroscale synthesis, reagents
and solvents are the dominant source of fluorine-19, while in microscale volumes,
these sources have been nearly eliminated and the fluorine-19 contribution from the
cyclotron dominates [44, 45] (Fig. 7.4). The effect of the 120 nm Teflon layer on the
chip was also investigated and no impact on SA was seen [43], perhaps due to the
radiolysis suppression effect described above.
Small volumes are extremely beneficial for another type of reaction, namely,
isotopic exchange (IEX). In IEX reactions, the precursor is identical to the final
product, except for the presence of fluorine-19 instead of fluorine-18, and cannot be
separated after synthesis. Thus it is desirable to minimize the amount of excess
















Fig. 7.4 Illustration of specific activity improvement. (Left) At the macroscale, reagents are the
dominant source of fluorine-19 contamination in the fluorination reaction mixture. (Right) At the
microscale, the reagents add negligible fluorine-19 contamination to that already present from the
cyclotron. After the fluorination reaction, the fluoride (both F-18 and F-19 forms) get incorporated
into the precursor and cannot be separated, resulting in 18F- and 19F-labeled forms of the tracer
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concentration of precursor needs to be sufficiently high for efficient reaction.
However, Perrin et al. have shown that small volume reactions are an effective
way to minimize precursor amount for IEX reactions [46, 47]. It should be noted
that the same principles can be applied to other carrier-added situations or to the
labeling of proteins or other species where the labeled and unlabeled forms cannot
be separated; in all such cases, it is critical to minimize the starting material in order
to obtain high SA. The dependence of SA on starting radioactivity for IEX reactions
was investigated in simplified EWOD chips using rhodamine clicked to an aryl-BF3
moiety [44]. Unlike in nucleophilic substitution reactions, SA of microfluidic IEX
reactions was found to vary with starting radioactivity, but in a nonlinear manner.
This suggests that perhaps the contribution of fluorine-19 from the cyclotron is
comparable to other sources and further reduced volume may be beneficial.
For both nucleophilic substitution and IEX reactions, small volume synthesis
can achieve high SA even from low starting amounts of radioactivity. This is in
contrast to macroscale synthesis, where high SA production typically requires
starting with Ci levels of radioactivity. Depending on the amount of tracer radio-
activity needed, small volume synthesis could therefore reduce the time/cost of
cyclotron bombardment, increase safety, and decrease the required amount of
shielding required for production.
7.3 Practical Considerations
7.3.1 Limits of Volume Reduction
Clearly there are enormous advantages to performing radiochemistry in small
volumes. The current EWOD chip geometry can reliably handle volumes as small
as ~2 μL, which is limited by the size of the electrodes that are used to load and
transport reagent droplets. Scaling down the volume of radiochemical reactions
below 2 μL could enable further reductions in precursor cost, further improvements
in specific activity (for IEX reactions or biomolecule labeling), further simplifica-
tion of purification and QC testing, or reduction in the size of the EWOD chip,
which leads to cost reduction. Even smaller droplets could be manipulated by
scaling down the electrode size and/or reducing the gap between the chip plates.
In fact, using specialized fabrication techniques, Nelson and Kim have shown that
droplets as small as 100 pL can be manipulated in an EWOD chip [48].
As the volume is scaled down, it is important to be mindful of several issues.
First, a certain minimum volume will be needed to solvate the desired amount of the
radioisotope complexed with phase transfer catalyst along with the precursor.
Another limitation will be the droplet lifetime: at extremely small volume scales,
droplets quickly evaporate and may not last sufficiently long to carry out the
fluorination reaction. The limit of volume reduction for radiochemistry applications
remains to be explored.
7 Advantages of Radiochemistry in Microliter Volumes 103
7.3.2 Radioisotope Concentration
When considering using small reaction volumes, one must also consider how to
produce sufficient quantity (radioactivity) of the tracer for the particular application
needed. For preclinical imaging, generally a few mCi is sufficient for a study
involving several animals, and with modern scanners, <25–50 μCi is sufficient
for a single mouse. On the other hand, imaging of a single patient requires on the
order of 10 mCi, while producing a large batch in a radiopharmacy for distribution
to imaging centers would require 100s–1000s of mCi. Even higher amounts of the
radioisotope are needed at the beginning of the synthesis due to nonideal yields and
fluid handling, as well as losses due to decay.
Cyclotrons can readily generate multiple Ci levels of [18F]fluoride in [18O]H2O
to satisfy any of these applications. However, the output volume is typically in the
milliliter range, while the capacity of the current EWOD chip (12 mm diameter
reaction zone x 150 μm droplet height) is only ~17 μL, i.e., 1 % of the volume from
the cyclotron. From a high-radioactivity bombardment, it would be possible to load
as much of tens of mCi of radioisotope into the chip without special measures, but it
is not desirable to waste the majority of the radioisotope, and several methods for
efficiently concentrating the radioisotope have been developed (Fig. 7.5a).
One approach is to concentrate the [18F]fluoride prior to loading it into the chip via
a solid-phase extraction (SPE) process. First, the [18F]fluoride/[18O]H2O is flowed
through a strong anion exchange cartridge (e.g., quaternary methyl ammonium,
QMA) to trap the [18F]fluoride. After removing residual water (e.g., with an inert
gas flow), an eluent solution (e.g., aqueous K2CO3/ K2.2.2 or tetrabutylammonium
bicarbonate (TBAB), sometimes with MeCN) is passed through the cartridge to
release the [18F]fluoride. If the cartridge has sufficiently small bed volume, the volume
of eluent solution needed to efficiently collect the [18F]fluoride can be quite low. For
example, using commercial cartridges (OPTI-LYNX, Optimize Technologies),
Elizarov et al. concentrated 92 % of 876 mCi starting [18F]fluoride into a ~5 μL
volume [15], our group demonstrated release into ~12 μL volume [49], and Lebedev
et al. [17] and Bejot et al. [50] demonstrated release into 44 μL volume. This approach
can be integrated with microfluidics by using packed-tubing cartridges [15],
functionalized porous polymer monoliths [51], packed microchannels [52], or resin-
filled inserts [12]. Control of trapping and release processes requires the use of valves
with small internal volumes to choose which solution is flowed into the cartridge inlet
(i.e., [18F]fluoride or eluent) and whether the cartridge outlet is direct to an [18O]H2O
collection reservoir or the microfluidic chip. Most commonly, this is accomplished
with HPLC injection valves, but can also be achievedwith on-chipmicrovalves if they
can be conveniently integrated into the device (Fig. 7.5b, c). Once loaded into the chip,
the concentrated [18F]fluoride solution is generally evaporated to dryness, and then the
subsequent fluorination reaction volume can be controlled by the volume of precursor
solution added, provided there is sufficient solvent to dissolve not only the precursor
but also the fluoride complex with phase transfer catalyst. Similar trap and release of
[18F]fluoride can be accomplished with microfluidic electrochemical flow cells
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Fig. 7.5 (a) Because the volume of batch microfluidic chips is much smaller than the volume of
the radioisotope source, concentration is necessary to ensure sufficient quantity of radioactivity
can be loaded onto the chip. (b) Cartridge-based method for concentration described in Ref.
[49]. Using an HPLC injection valve with small internal volume, the flow path can be configured in
trapping mode, where the [18F]fluoride/[18O]H2O is flowed through a micro-cartridge and the [
18F]
fluoride trapped, or a release mode, where a small volume of eluent solution is passed through the
cartridge to release the [18F]fluoride and deliver it onto the chip. (c) Cartridge-based method using
on-chip microvalves implemented in a polydimethylsiloxane (PDMS) chip. Pressure applied to
“control channels” can open or close nearby “fluid channels” to configure the flow path into
trapping and release modes (Adapted from reference [15] © by the Society of Nuclear Medicine
and Molecular Imaging, Inc.). (d) Scheme for evaporative concentration of [18F]fluoride radio-
isotope. The top images show cross-sectional schematics of the concentration process, and the
bottom images show Cerenkov (radioactivity) images of the top view of the chip at corresponding
times. Orange lines and circles were added to depict the cover plate edge and the reaction site,
respectively. Initially, a 200 μL droplet of [18F]fluoride solution is loaded to the cover plate edge.
By activating a nearby heater, the volume of the droplet is reduced to ~5 μL and then pulled into
the chip by electrode actuation. (Reproduced from Ref. [25] with permission from the Royal
Society of Chemistry.)
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[53, 54] where the [18F]fluoride is trapped at an electrode surface by application of
positive voltage.
A different approach is to perform the [18F]fluoride concentration directly on
chip [25]. A special chip was fabricated where the bottom plate extended beyond
the edge of the cover plate to create a platform. A large droplet of [18F]fluoride
solution (with phase transfer catalyst) was loaded onto this platform adjacent to the
gap between the two EWOD chip plates and then rapidly evaporated down to a
small volume that could be transported between the plates (Fig. 7.5d). Because
some groups have reported that the anion exchange resin can contribute fluorine-19
contamination [55], this approach may reduce the amount of fluorine-19 in the
reaction mixture and thus enable production of PET tracers with higher specific
activity. It also has the advantage of not requiring any valves, but the disadvantage
of requiring larger chip real estate.
With any of these approaches, it is possible to concentrate a significant fraction
of the radioactivity from a cyclotron bombardment into a volume that can be loaded
onto the microfluidic chip, enabling radiochemistry to be performed in microliter
volumes with high radioactivity.
7.3.3 Synthesis Automation
As with radiosynthesis in conventional systems at milliliter volume scales, it is
important that the apparatus is operated in an automated fashion within radiation
shielding to ensure the safety of the operator preparing the PET tracer. Fully
automated synthesizers have been developed based on some of the earlier reports
of batch microfluidic chips, complete with reagent delivery, radioisotope concen-
tration, synthesis, and cartridge-based purification or interfacing with an HPLC
system [15, 17, 50, 56].
For the more recent EWOD microfluidic platform, many aspects of automating
the overall system have been demonstrated. Two approaches have been developed
for loading reagents from off-chip reservoirs (e.g., standard septum-capped glass
reagent vials) into the chip. One simple approach uses an electronically controlled
syringe pump to precisely dispense the desired volume of reagent after compensat-
ing for evaporation losses at the dispensing tip [57]. Another approach was devel-
oped in collaboration with Sofie Biosciences, Inc. to avoid the use of complex,
difficult-to-clean components such as syringe pumps and valves, instead of relying
on simple disposable fluidic elements such as needles and tubing. Inert gas pressure
and gravitational force were used to apply forward and reverse driving forces,
respectively, to deliver repeatable volumes to the chip [58]. A multi-reagent loading
interface was developed based on this principle and was integrated with a simple
cartridge-based method for upstream [18F]fluoride concentration and an automated
method for downstream collection of the crude product from the chip and interfac-
ing with miniature solid-phase extraction cartridges or analytical-scale HPLC for
purification [34]. Some preliminary progress to develop methods for on-chip
purification has also been made including removal of unreacted [18F]fluoride
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using an alumina surface [35] or beads [36], and more complete separation may be
possible by performing on-chip solid-phase extraction. A prototype of a complete
EWOD-based PET tracer production system suitable for benchtop operation is
under development at Sofie Biosciences in collaboration with our group.
7.4 Conclusions and Outlook
The development of batch microfluidic devices may provide an ideal platform to
harness the numerous advantages of performing the synthesis of PET radiotracers in
small volumes, including reduced reagent consumption, improved specific activity,
reduced radiolysis, and synthesizer miniaturization. In particular, the EWOD plat-
form is compatible with diverse reaction conditions and provides a convenient
means to digitally manipulate droplets to perform diverse multistep reactions. By
combining these devices with technologies for concentration of radioisotopes into
an automated platform, it will become possible to produce not only batches on
demand for research use but even large-scale batches in a radiopharmacy for
distribution purposes. This microvolume radiochemistry technique could also be
a particularly good match for isotopic exchange and biomolecule labeling reactions
and could enable novel chemistries by boosting [18F]fluoride concentration by
orders of magnitude. As a tool for remotely and safely handling small volumes,
the EWOD microfluidic platform could open up opportunities for researchers to
uncover additional benefits of radiochemistry in extremely small volumes.
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